Samsung Bioepis Eyes US Trastuzumab Potential As It Hits Profitability
Firm Recently Entered Crowded US Trastuzumab Market With Ontruzant
In an exclusive interview, the executive vice-president for Samsung Bioepis’ commercial division, Sang-Jin Pak, tells Generics Bulletin there is plenty of opportunity remaining in the crammed US trastuzumab market and explains what an achievement it was for the South Korea-based company to reach profitability only eight years after inception.
You may also be interested in...
The planned spin-off of Merck & Co’s Organon unit, with annual sales of $6.5bn including from biosimilars, is nearing completion, with the originator filing documentation with the SEC and unveiling a progressive female-majority board of directors for the new company.
Merck & Co has disclosed more precise details around plans to spin off its more mature products, including biosimilars, into a new publicly traded company.
Amgen enters 2021 with a five-strong global biosimilars portfolio, spearheaded by its market-leading bevacizumab and trastuzumab products in the US. Management explained the contrasting fates of the two oncology biosimilars as it published full-year financial results.